ExodusPoint Capital Management’s CorMedix CRMD Stock Holding History

ExodusPoint Capital Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-62,549	Closed	-$771K	–	1616
2025 Q2	$771K	Sell	62,549 -168,918	-73%	-$1.86M	0.01%	1037
2025 Q1	$1.43M	Buy	231,467 +152,178	+192%	+$1.58M	0.01%	821
2024 Q4	$642K	Buy	79,289 +30,424	+62%	+$304K	﹤0.01%	1079
2024 Q3	$395K	Buy	+48,865	New	+$264K	﹤0.01%	1277
2022 Q4	–	Sell	-15,298	Closed	-$43K	–	1714
2022 Q3	$43K	Buy	+15,298	New	+$63.6K	﹤0.01%	1795
2021 Q3	–	Sell	-21,310	Closed	-$146K	–	2191
2021 Q2	$146K	Buy	+21,310	New	+$170K	﹤0.01%	2064
2021 Q1	–	Sell	-26,229	Closed	-$195K	–	2177
2020 Q4	$195K	Buy	+26,229	New	+$178K	﹤0.01%	1738
2020 Q1	–	Sell	-23,003	Closed	-$167K	–	1159
2019 Q4	$167K	Buy	+23,003	New	+$141K	﹤0.01%	1370
2019 Q2	–	Sell	-37,255	Closed	-$352K	–	1134
2019 Q1	$352K	Buy	37,255 +22,815	+158%	+$206K	0.03%	423
2018 Q4	$93K	Buy	+14,440	New	+$96.6K	0.01%	315

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ExodusPoint Capital Management's CRMD Position: Q3 2025 in Review

ExodusPoint Capital Management sold out of CorMedix (CRMD) in Q3 2025, closing a stake of 62,549 shares — an estimated $771K sold.

ExodusPoint Capital Management first reported a position in CRMD in Q4 2018 and held it in 10 quarters. The position peaked at $1.43M in Q1 2025. 190 funds tracked by Wall St. Rank hold CRMD as of Q3 2025.

ExodusPoint Capital Management reported no remaining CorMedix position as of Q3 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 62,549 CorMedix shares in Q3 2025, an estimated $771K.
ExodusPoint Capital Management first reported a position in CorMedix in Q4 2018 and held it in 10 quarters.
ExodusPoint Capital Management's CorMedix position peaked at $1.43M in Q1 2025.
190 funds tracked by Wall St. Rank held CorMedix as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.